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To assess additional value of prostate- 
in the diagnosis of prostate
376 patients
cancer in patients who undergo 
Patients and methods The study 
with symptoms of prostatism who were 
prostate biopsy. Digital rectal examination (DRE) and 
transrectal ultrasonography (TRUS) were performed
and specific antigen (PSA) and
density (PSAD) were determined for each patient. 
Results Both PSA and PSAD significantly differentiated 
(P< 0.001) between benign and malignant histology. 
Of the 376 patients, 91 (24%) had a PSA level in
the intermediate range (4.0 ng/mL)
patients PSAD was significantly better than PSA
92% and the specificity was 54% for 
prostate cancer. No patient with a
diagnosis of 
biopsy had
a PSAD < 0.11  ng/mL/cm3. No limiting value could 
be found for PSAD that combined both an acceptable
patients a
sy, 92% also had a
¿ IIS P '" " J-
Conclusion In patients with intermediate PSA levels, 
PSAD is of limited additional value when compared to 
DRE in correctly diagnosing prostate cancer. Acute 
prostatitis is also a possible cause of elevated PSA. 
Both PSA and PSAD had no additional value in 
differentiating between benign prostatic hyperplasia 
(BPH) and histologically proven extensive prostatitis.
in differentiating between benign and malignant Keywords Prostate cancer, benign prostatic hyperplasia,
histology (P With
0.15 ng/mL/cm3 in these patients, the sensitivity was
prostate-specific antig
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Introduction
Digital rectal examination (DRE), transrectal ultrasono­
graphy (TRUS) and prostate-specific antigen (PSA) are 
commonly used as diagnostic tools in the early detection
of . None of these tests has sufficient
accuracy to justify its use alone as a scree 
combination of DRE, TRUS and 
to predict the presence of carcinoma 11 ].
Although 
cancer in
•es
test. The 
ability
is accurate mi for
; prostate, its sensitivity ;
are insufficient. Consensus exists that for a PSA value 
< 4  ng/mL, where the incidence of prostate cancer is
PSA may be found in patients with BPH or after prostatic 
manipulations such as cystoscopy and prostate biopsy
half-life of PSA is estimated to be 2.2
[7] to 3.2 days it may, i on j rise m
level, take 2 -3  weeks after prostatic manipulation before 
the PSA serum level has decreased to its base-line value.
Because prostatic volume may iniluence the PSA level 
it is prudent to make a correction for prostatic volume 
(PSA/prostatic volume =  PS A-density, PSAD) as proposed 
by Benson et al. [9'J. An overview of the results of several 
studies is shown in Table 1; there is still much debate 
about the clinical value of PSAD.
According to Benson et a i  151, patients , a
1.4% sies are not i if there is no further PSAD < 0 .15  ng/mL/cm1 and a normal Dilli may be
suspicion lbr malignancy. At a PSA level > 1 0  ng/mL, 
the incidence of prostate cancer is 53.3% (3 J and most 
authors [4,5] agree that biopsies have to be taken in 
these cases. In the range between 4 and 10 ng/mL PSA
(intermediate PSA levels, i 
benign prostatic 
frequently occur in patients
diagnosis is
:rplasia
as
or prostate cancer
iPSA. An increase m
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treated by watchful waiting, as re is only an 18%
chance of them having a positive biopsy. Bazinet el al.
also used a limit for PSAD of 0.1 5 ng/mL/cm1, 
below which only 3% of patients had a positive biopsy. 
Ramon et al polyclonal Yang
Vc to
equal to
in their study but, conver 
of the Hybritech assay, and for a 
0.15 ng/mL/cm3, they found a 42% incidence of prostate 
cancer in the PSA range of 1 .7-6.7 ng/mL and a 51%
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Table 1 Publications evaluating the role of PSAD in all patients and in those with intermediate PSA levels
Total group PSA range 4 .1 -1 0 ,0  ng/mL
Publication
Patients
(n)
%
biopsictl
Positive
biopsy
(%)
% of total 
group
Positive
biopsy
(%)
Limit
for
PSAD
Positive
biopsy 
< limit (%)
[5] 3140 49.2 31.2 13.6 27.0 0.15 18*
[1 2 ] 218 1 0 0 31.2 49.1 28.0 none —
[1 0 ] 565 1 0 0 40.6 25.1 16.2 0.15 3
[HI 495 1 0 0 50 23.6f 28.7 0.15 42*
28.3$ 42.4 0.15 51*
Present study 376 1 0 0 30.1 24.2 1 2 . 1 0 . 1 1 0
0.15 2.3
*% positive biopsies when PSAD is equal to 0.15 ng/mL/cm3. tPSA of ,1.7-6.7 ng/mL. :|:PSA of 6 .7-13.3 ng/mL
incidence in the PSA range of 6.7-13.3 ng/mL. In prostatic or urethral manipulation (e.g. cystoscopy) or
contrast, Brawer et al [12] found that PSAD was not within 4 weeks of acute prostatitis. DRE was considered 
able to discriminate between patients with prostate not to influence the PSA level, according to recent 
cancer and those with BPH in this range. Several other studies [22-24].
studies [13-18] confirmed that PSAD was superior to 
PSA in differentiating prostate cancer from BPH. These
TRUS examinations were performed using a Kretz 
Combison 330 scanner with a 7.5 MHz probe (Multi­
studies are not listed in Table 1 because they do not plane 3-D VRW 77AK) and were carried out by one
provide enough data in the iPSA range.
To evaluate the clinical value of PSAD in the iPSA 
range, the correlations of PSAD, PSA, DRE and TRUS 
with the results of histopathological examination of Biopty gun (C.R. Bard, Covington, USA), using 18 G
urologist experienced in performing TRUS. Prostatic 
volume was calculated using a planimetric method incor­
porated in the scanner. Biopsies were taken with the
patients who underwent transrectal biopsies were 
retrospectively investigated. Increases in PSA also occur
‘Tru-cut’ biopsy needles. If a hypoechoic lesion was seen, 
a core was taken from that region. In 76% of the
during acute prostatitis [19-21]. A histologically distinct patients, three cores were taken from the right and left
feature of acute prostatitis is the invasion of white blood sides, equidistant from the base and apex, in 20% two
cells into the prostatic ducts. These are predominantly cores were taken from each side of the prostate and in
polymorphic, rather than mononuclear, white blood 
cells. This invasion may cause a leakage of PSA from 
the ductal lumina, as the integrity of the prostatic ducts 
is disturbed. Therefore, we investigated whether PSAD
4% only ultrasound-guided biopsies were taken. The 
cores were sectioned and stained with haematoxylin and 
eosin. On the basis of these sections patients were then 
assigned to either a benign or a malignant group.
or PSA was significantly higher in patients for whom Analyses were performed on data from the whole group
we had histological proof of extensive acute inflammation 
of the prostate.
Patients and methods
Between January 1991 and December .1993, transrectal
and separately on the patients with iPSA. Additional 
analyses were performed using the PSA levels of patients 
with histologically proven extensive prostatitis.
Significance was evaluated using the Mann-Whitney 
U'test and the x2-tests. Receiver operator characteristic 
(ROC) curves, graphically representing the correlation
biopsy of the prostate was performed in 376 men (mean between sensitivity and the false positive fraction, were 
age 69.1 years, range 48.4-97.5), till of whom had constructed to determine the optimal limits for PSA and
micturition complaints.
Indications for biopsy were a suspect nodule on DRE,
PSAD. A perfect test would have a 100% sensitivity and 
a 0% false positive rate with an area under the curve of
a hypoechogenic lesion on TRUS or a PSA value one. The usefulness of a diagnostic test is assessed by
> 1 0  ng/mL. All patients underwent TRUS, DRE and calculating the fractional area under the ROC curve. A
had their serum PSA level determined using the multivariate analysis was also performed to assess the
Tandem-E PSA assay (Hybritech, San Diego, CA, USA). individual value of DRE, TRUS, PSA and PSAD in the
No blood samples were used if they were taken within detection of prostate cancer. 
2 weeks of acute urinary retention, within 3 weeks of
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Table 2  PSA levels, prostatic volume and PSAD in > 76 patients who underwent prostate biopsies
Number (%)
Meditili PSA
(ng/mL [ range ¡)
Median volume 
(ciii3 (range])
Median PSAD 
(ng/mL/cm3 ¡range!)
All patients 
Benign 
Malignant 
2-tailed P
376
263 (69.9) 
113 (30.1)
1.2.0 (0 .5-3100)  
9.60 (0 .5-190)  
3 3.0 (1 .6-3100)  
< 0 . 0 0 1
47.5 (11-202)  
51.0 (11-202)  
39.3 (16-1.45) 
< 0 . 0 0 1
0 . 2 2  (0 .0 1 - 
0.17(0 .01-  
0.91 (0.07- 
< 0 . 0 0 1
- 1 0 0 )
3.0)
- 1 0 0 )
Results
Total group
A moan of 6.1 cores per patient was taken for biopsy 
and in 71.6% of the patients at least six cores were 
taken. The histological examination revealed prostate 
cancer in 113 patients (Table 2).
Five patients with an initial benign histology were 
biopsied again within 1 year and were proved to have 
prostate cancer. The second biopsy was performed 
because the initial histological diagnosis was suspect 
(two patients) or there was a rise in PSA level (three 
patients). These patients were reclassified as having a 
malignant tumour.
The mean PSA level was 9.6 ng/mL in the patients 
with a benign diagnosis and 3 3.0 ng/mL in those with 
malignancies. Although 95.6% of the patients in the 
benign group had a PSA < 7 8  ng/mL, there were two 
patients with BPH and a PSA level > 7 8  ng/mL. One 
patient with a PSA level of 190 ng/mL underwent 
transurethral resection of the prostate and 150 g of 
tissue was resected. Histological examination showed 
focal abscesses. The mean PSAD was 0..17 ng/mL/cm3 
in the benign group and 0.91 ng/mL/cm5 in the malig­
nant group. The PSA level, prostate volume and PSAD 
were significantly different between the benign and the 
malignant group (P < 0.001). The area under the ROC 
curves for PSA (0.816) and PSAD (0.858) in the whole 
group were not significantly different (Fig. 1).
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Fig. 1 . Receiver operator characteristic curve lor I’SAI) and PSA 
in the whole group (376 patients). — PSAD. - - - PSA,
Tabic 3 Reliability of DRH, and TRUS when DRH was normal, in 
the detection of prostate cancer
Benign
n (% of group)
Malignant 
n (% of group)
Total 
in group
DRI3 normal 169 («8 ) 22  ( 1 2 ) 191
DRIÎ abnormal 94 (5 3) 91 (47) 185
Total 26 3 113 376
TRUS normal 1 19 (91) 12 (9) 131
TRUS abnormal 50 ( 8  3) 1 0  (17) 60
Total 169 2 2 191
DRH and TRUS Prostatitis
In the group with a negative DRH, 22 ( 12%) had prostate
cancer compared to 91 (47%) with a DRE
(Table 3, P <  0.001). For patients with a negative DRE, 
TRUS was of no additional value (Table 3, P — 0.1 31 ). 
However, when TRl.IS showed no abnormality, DRE was 
able to differentiate between malignant and benign biops­
ies (P =  0.01.1). In the group with a normal DRE, both 
PSAD and the PSA level could differentiate between 
malignant and benign biopsies (Table 4).
In the benign group, 13 patients ( 3.5%) had biopsies 
but with moderate to extensive invasion of polymorphic 
white blood cells and the biopsies were histologically 
classified as prostatitis. There was no significant differ­
ence between the prostatitis group and the benign group 
but with no prostatitis in PSA level, prostate volume or 
PSAD (P= 0 .06 , P = 0 .06  and P = 0.47, respectively). 
DRE findings were more often classified as malignant 
in the prostatitis group than in the benign group
& 1995 British Journal of Urology 76, 4 7 - 5 3
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Table 4 PSA, prostate volume, and PSAD in patients with no abnormal findings on DRE and in the patients with a PSA between 
4.0 ng/mL and 10.0 ng/mL (iPSA)
Number (%)
Median PS'A 
(nglmL [range])
Median volume 
(cm3 [range})
Median PSAD 
(ng/mL/cm3 [range])
Negative DRE 191 1 2 . 0  (0.5-260) 53.6 (13-202) 0 . 2 0  (0.01-8.67)
Benign 169 (88.5) 11.0 (0.5-190) 54.0 (13-202) 0.19 (0.01-3.0)
Malignant 22 (11.5) 16.5 (8.0-260) 43.8 (20-145) 0.34 (0.12-8.67)
2 -tailed P 0 . 0 0 2 0.207 < 0 . 0 0 1
iPSA 91 6.9 (4.1-9.9) 49.0 (20.3-180) 0.15 (0.03-0.35)
Benign 79 (8 6 .8 ) 6 . 8  (4.1-9.9) 50.0 (20.3-180) 0.13 (0.03-0.35)
Malignant 12 (13.2) 7.5 (5.8—9.9) 40.0 (29.0-81.0) 0.19 (0.11-0.25)
2 -taiJed P 0.316 0.0815 0.027
(P=0.009), whereas TRUS did not differ between these One biopsy from a patient with a PSAD below this limit
groups (P = 0.536).
iPSA
Ninety-one patients had iPSA levels. A mean of 6.2 cores
appeared to be malignant. Of the 79 benign biopsies 43 
(54%) had a PSAD <0.15 ng/mL/cm3. None of the 
12 patients with a malignant biopsy had a PSAD 
< 0.11  ng/mL/cm3 compared with 27 of the 79 benign 
biopsies (34%). The performance for different values of
per patient were taken during biopsy and in 74.7% of PSAD is given in Table 5. For some PSAD limits, sensi-
these patients six or more cores were taken. In 12 patients 
the biopsies appeared malignant and in 79 they were 
benign (Table 4). PSAD was significantly different (P= 
0,027) between the patients with a benign or a malignant 
histology but PSA level did not differ significantly (P=  
0.316). ROC curves were plotted for PSA and PSAD 
(Fig. 2) giving an area under the curve of 0.59 for PSA 
and 0.70 for PSAD, which was significantly different, 
indicating that PSAD was superior to PSA in differen­
tiating between benign and malignant prostatism.
Following the recommendation of Benson et al [5], a 
PSAD limit of 0.15 ng/mL/cm3 was used for diagnosis.
100
80
■S'
■>
60
l«l
o . i 5  o s — 0 — e-
e
0)c
CD
C/)
40
20
— e -
^ ° * 16 
/CU7
r  /
M M
0.11 0.10
a i 4 0 . 1 3 ° - 12 I//
//
|  MW J
I
//
I
/
t I//
0 20 40 60 80 100
(1-specificity) cq. % false positives (%)
Fig. 2. Receiver operator characteristic curve for PSAD and PSA 
in patients with a PSA level between 4.0 and 10.0 ng/mL. 
PSAD. - - - PSA.
tivity and specificity are given if these values were taken 
as the upper limit, below which the PSAD was a predictor 
of benign histology and above which malignant histology 
could be predicted.
Table 6 gives the performance of DRE and TRUS in 
this group. DRE findings correlated well with the 
histological outcome ( P = 0.004) while TRUS could not 
discriminate significantly between malignant and benign 
tissue (P = 0.300).
Discussion
The detection of early prostate cancer depends on the 
accuracy of DRE, TRUS and serum PSA, which are 
currently considered to be the best tools for the diagnosis
Table 5 Performance of different PSAD limits in patients with PSA 
levels between 4.0 ng/mL and 10.0 ng/mL
Upper limit 
of PSAD 
(ng/mL/cmJ)
Sensitivity (%)
Specificity (%) 
(potentially 
saved biopsies)
False
positives/ total 
positives (%) 
(unnecessary 
biopsies)
0 . 1 0 1 0 0 19 81
0 . .11 1 0 0 32 6 8
0 . 1 2 9 9V iw 39 61
0.13 92 44 56
0.14 92 51 49
0.15 92 54 46
0.16 67 65 35
0.17 58 71 29
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Table 6  Reliability of DRE and TRUS in patients with a PSA 
between 4.0 and 10,0 ng/mL
serum PSA divided by the prostatic volume measured by 
TRUS, is consistent with values of PS AD calculated as the
Benign
n (% of group)
Malignant 
n (% o f group)
Total 
in group
DRE normal 42 (98) 1 (2 ) 43
DRE abnormal 37 (77) 11(23) 48
Total 79 1 2 91
TRUS normal 39 (91) 4 (9 ) 43
TRUS abnormal 40 (83) 8  (17) 48
Total 79 1 2 91
change in serum PSA divided by the weight of resected 
tissue after TURP. However, PS AD values obtained by 
PSA measurement before and after TURP vary among 
different authors. Stamey et al. [7], calculated a value of 
0.5 (± 0 .4 ) ng/mL/cm3 while Lee et al. [15] found a 
value of 0.12 ng/mL/cm3.
Some authors think that PSAD is of little or no value 
in discriminating between prostate cancer and 13PH and 
suggest that age-specific PSA values are more useful 
than PSAD [28]. As prostatic volume increases with age, 
a higher limit lor the lower threshold of the normal PSA
of prostate cancer [3]. However, the accuracy of PSA in
range in older men in itself implies a correction for 
higher prostate volumes in older men.
differentiating patients with prostate cancer from those The aim of this retrospective analysis was to investi-
with benign disease is insufficient, according to some gate whether PSAD-based clinical guidelines could help
authors [7,25]. In the iPSA range there is an overlap of in the diagnosis of prostate cancer and assist in avoiding
PSA levels in patients with prostate cancer and those a significant number of biopsies. In the study, most TRUS
with benign disease. was performed immediately after DRE. The subsequent
PSAD promised to be a better tool in differentiating interpretation of TRUS can be biased, because the out-
between patients with BPH and prostate cancer [13]. All come of DRE (and PSA) may influence the interpretation
but one of the studies mentioned in Table 1 confirmed 
the findings of Benson [5] that PSAD is superior to PSA 
in differentiating between benign and malignant pros-
of the TRUS image. However, TRUS had no significant 
extra value when combined with DRE in the detection 
of prostate cancer (P =  0.131). Because all patients were
tates in the iPSA range. A limit of 0.15 ng/mL/cm3 was referred for micturition complaints many in the benign
chosen by these authors, but the choice of a threshold group inevitably presented with a high prostate volume.
value of PSAD depends on the desired sensitivity for the 
detection of prostate cancer. A balance must be found
This could explain the significantly 
volume in this group compared to
prostate 
group with
between an acceptable proportion of undetected prostate prostate cancer (Table 2), an effect which was also seen
cancers and the lowest possible proportion of unneces by Benson et al. [ 5].
sary biopsies. Overall, PSAD made no significantly better distinction
The reliability of PSAD is a product of the reliability between patients with prostate cancer and those with
of its constituents; the accuracy of PSAD obviously BPH . 1). In the iPSA range only 12.1% of the
depends on the accuracy with which the PSA and patients appeared to have prostate cancer, which is the
prostatic volume are assessed. The production of PSA lowest rate of the studies quoted in Table 1, possibly
per volume of prostatic tissue is not only related to the because the present study was comprised of patients
presence of BPH and prostate cancer but also to the with micturition complaints. In this group, the mean
proportion of epithelial cells and to the histological grade prostate volume was higher when compared to a screen-
of the carcinoma. Hormonal status and other factors 
may also play a role. Assessment of the prostatic volume
ing population which may explain why these patients 
more often had a PSA value > 4 .0  ng/mL.
depends on many factors and can be calculated by the In the iPSA range, the sensitivity was '100% and the
or planimetrie methods. The calculation of specificity 32% for the diagnosis of prostate cancer when
the prostatic volume in the first three articles listed in a PSAD limit of 0,11 ng/mL/cm1 was used. If a limit of
Table 1 was made using the method (i.e. 0.1 5 ng/mL/cm3 was used the values were 92 and 54%,
0.52 x length x width x height). Stone et al. [26] found respectively. No limit could be found that combined
that step-section 3D-planimetry gave a variability of 5% a good sensitivity and a good specilicity (Table 5).
compared with 30% for a three-axis method. According Moreover, of the 1.2 patients in this range who had
to Holmang et al. [27] the ellipsoid method underesti- prostate cancer, 11 had a suspect DRE. This finding is
mates the volume by 20%) compared with the planimetry not surprising, as patients with a normal DRE were only
of several sections, but they are well correlated with biopsied if TRUS was abnormal and, as indicated, TRUS
each other. The planimetrie method, as used in the is an inaccurate means of detecting early prostate cancer.
present study, seems the most accurate. PSAD was of no additional value to DRE in differentiating
Moreover, one would expect that PSAD, calculated as between prostate cancer and benign disease in the iPSA
© 1995 British Journal of Urologi/ 76, 4 7 - 5  3
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range. This might be explained by selection of
patients, as patients with an iPSA level, a normal TRUS 
and a normal DRE were not biopsied.
Conclusions
The PSAD limit chosen is not an absolute value as it 
depends on the population examined, the reliability of the 
measurement of prostatic volume and the desired sensi­
tivity. In patients with micturition complaints and an 
iPSA level, a PSAD <0.15 ng/mL/cm3 indicates a high 
probability (97.7%) of benign histology, but the PSAD is 
of limited additional value to DRE. Both PSA and PSAD 
had no significant value in differentiating between 
histologically proven extensive prostatitis and BPH.
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